Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by University of Hawaii.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
University of Hawaii Identifier:
First received: January 26, 2012
Last updated: January 30, 2012
Last verified: January 2012
The goal of this clinical trial is to improve and personalize pancreatic cancer care to deliver the most effective therapy while avoiding unnecessary exposure to potential side effects. Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are much more likely to respond to cisplatin than those whose tumors produce large amounts. The hypothesis is that the combination of gemcitabine and oxaliplatin is a uniquely effective regimen for patients with metastatic pancreatic cancer whose tumors have a low expression of ERCC1.

Condition Intervention Phase
Metastatic Pancreatic Cancer
Drug: gemcitabine and oxaliplatin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 (Excision Repair Cross-complementation Group 1)

Resource links provided by NLM:

Further study details as provided by University of Hawaii:

Primary Outcome Measures:
  • 6 month overall survival [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival [ Time Frame: Assessments every 2 months until 2 years or death ] [ Designated as safety issue: No ]
  • Progression free survival [ Time Frame: Assessments every 2 months with CT scan until progression by RECIST criteria up to maximum of 2 years ] [ Designated as safety issue: No ]
  • Best confirmed response [ Time Frame: Assessments every 2 months with CT scan until progression by RECIST criteria up to maximum of 2 years ] [ Designated as safety issue: No ]
  • Duration of overall response [ Time Frame: Assessments every 2 months with CT scan until progression by RECIST criteria up to maximum of 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: January 2012
Estimated Study Completion Date: January 2014
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: ERCC1 high expression
Patients with ERCC1 high expression tumors will be treated at discretion of investigator
Experimental: ERCC1 low expression
Patients with ERCC1 low expression will be treated with gemcitabine and oxaliplatin
Drug: gemcitabine and oxaliplatin
gemcitabine 1000mg/m2 IV q2week and oxaliplatin 85mg/m2 IV q2week


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma
  • Patients must not have had prior chemotherapy or biologic therapy for metastatic pancreatic cancer
  • Prior adjuvant chemotherapy for completely resected disease or chemoradiotherapy for locally advanced disease is allowed but must have been administered > 6 months prior to registration
  • ECOG Performance Status of 0, 1, or 2
  • Adequate hematologic, hepatic and renal function

Exclusion Criteria:

  • Pregnant or nursing women
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for 5 years
  • Patients must not have known brain metastases
  • Any other condition that in the opinion of the Investigator may render the patient at excessive risk for treatment complications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01524575

Contact: Jared D Acoba, MD 8085318521

United States, Hawaii
University of Hawaii Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Jared D Acoba, MD    808-531-8521   
Sponsors and Collaborators
University of Hawaii
Principal Investigator: Jared D Acoba, MD University of Hawaii Cancer Research Center
  More Information

No publications provided

Responsible Party: University of Hawaii Identifier: NCT01524575     History of Changes
Other Study ID Numbers: CRCH0904 
Study First Received: January 26, 2012
Last Updated: January 30, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Hawaii:
pancreatic cancer

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Pancreatic Diseases
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on February 09, 2016